Brokers Issue Forecasts for Ultragenyx Pharmaceutical Inc.'s Q4 2023 Earnings (NASDAQ:RARE)
Brokers Issue Forecasts for Ultragenyx Pharmaceutical Inc.'s Q4 2023 Earnings (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q4 2023 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a report issued on Wednesday, February 1st. Jefferies Financial Group analyst M. Raycroft forecasts that the biopharmaceutical company will post earnings per share of ($1.37) for the quarter. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($8.84) per share.
Ultragenyx制药公司(纳斯达克:Rare-Get Rating)-杰富瑞金融集团的股票研究分析师在2月1日星期三发布的一份报告中发布了他们对Ultragenyx制药公司2023年第四季度每股收益的估计。杰富瑞金融集团分析师M.Raycroft预测,这家生物制药公司将公布本季度每股收益为1.37美元。对Ultragenyx制药公司目前全年收益的普遍估计是每股8.84美元。
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last released its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.29) by ($0.14). Ultragenyx Pharmaceutical had a negative return on equity of 84.14% and a negative net margin of 197.47%. The business had revenue of $90.70 million during the quarter, compared to the consensus estimate of $98.76 million.
超凡药业(纳斯达克:Rare-Get Rating)最近一次发布季度收益数据是在11月2日周三。这家生物制药公司公布了该季度每股收益(2.43美元),低于普遍预期的(2.29美元)和(0.14美元)。Ultragenyx制药公司的净资产回报率为负84.14%,净利润率为负197.47%。该业务本季度的收入为9070万美元,而普遍预期为9876万美元。
Ultragenyx Pharmaceutical Stock Performance
Ultragenyx制药类股表现
NASDAQ RARE opened at $45.73 on Friday. Ultragenyx Pharmaceutical has a one year low of $33.36 and a one year high of $85.53. The stock has a 50-day moving average of $43.04 and a 200 day moving average of $43.66. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -4.70 and a beta of 0.96.
纳斯达克Rare上周五开盘报45.73美元。Ultragenyx Pharmtics的一年低点为33.36美元,一年高位为85.53美元。该股的50日移动均线切入位在43.04美元,200日移动均线切入位在43.66美元。该公司市值为32.1亿美元,市盈率为-4.70倍,贝塔系数为0.96。
Insiders Place Their Bets
内部人士下注
In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 2,031 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Wednesday, December 21st. The stock was sold at an average price of $43.96, for a total value of $89,282.76. Following the sale, the chief accounting officer now owns 16,197 shares of the company's stock, valued at approximately $712,020.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.70% of the company's stock.
在Ultragenyx制药公司的其他新闻中,首席财务官西奥多·艾伦·惠曾加在12月21日星期三的一笔交易中出售了2,031股Ultragenyx制药公司的股票。这只股票的平均售价为43.96美元,总价值为89,282.76美元。出售后,首席会计官现在拥有16,197股公司股票,价值约712,020.12美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。公司内部人士持有该公司6.70%的股份。
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
对冲基金入股Ultragenyx制药公司
Several large investors have recently modified their holdings of RARE. Raymond James & Associates increased its position in shares of Ultragenyx Pharmaceutical by 46.0% during the 1st quarter. Raymond James & Associates now owns 13,882 shares of the biopharmaceutical company's stock valued at $1,008,000 after purchasing an additional 4,373 shares during the last quarter. US Bancorp DE increased its position in shares of Ultragenyx Pharmaceutical by 14.6% during the 1st quarter. US Bancorp DE now owns 8,611 shares of the biopharmaceutical company's stock valued at $625,000 after purchasing an additional 1,097 shares during the last quarter. Bank of Montreal Can boosted its holdings in Ultragenyx Pharmaceutical by 22.7% during the 1st quarter. Bank of Montreal Can now owns 40,319 shares of the biopharmaceutical company's stock valued at $2,927,000 after acquiring an additional 7,469 shares during the period. MetLife Investment Management LLC purchased a new position in Ultragenyx Pharmaceutical during the 1st quarter valued at $252,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Ultragenyx Pharmaceutical by 44.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 463,996 shares of the biopharmaceutical company's stock valued at $33,693,000 after acquiring an additional 141,945 shares during the period. Institutional investors own 93.17% of the company's stock.
几家大型投资者最近调整了对Rare的持股。Raymond James&Associates在第一季度将其在Ultragenyx制药公司的股票头寸增加了46.0%。Raymond James&Associates现在拥有这家生物制药公司13,882股股票,价值1008,000美元,在上个季度又购买了4,373股。US Bancorp DE在第一季度将其在Ultragenyx制药公司的股票头寸增加了14.6%。US Bancorp DE现在持有这家生物制药公司的8,611股股票,价值62.5万美元,此前在上个季度又购买了1,097股。蒙特利尔银行可以在第一季度增持Ultragenyx制药公司22.7%的股份。蒙特利尔银行现在可以持有这家生物制药公司40,319股股票,价值292.7万美元,在此期间又购买了7,469股。大都会人寿投资管理公司在第一季度购买了Ultragenyx制药公司的一个新头寸,价值25.2万美元。最后,Dimension Fund Advisors LP在第一季度将其在Ultragenyx Pharmtics的持股增加了44.1%。Dimension Fund Advisors LP现在拥有这家生物制药公司463,996股票,价值33,693,000美元,在此期间额外购买了141,945股票。机构投资者持有该公司93.17%的股票。
About Ultragenyx Pharmaceutical
关于Ultragenyx制药公司
(Get Rating)
(获取评级)
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Ultragenyx制药公司是一家生物制药公司,从事治疗严重罕见和超罕见遗传病的新产品的识别、收购、开发和商业化。其产品包括Mepsevii和Crysvita。Mepsevii是一种静脉酶替代疗法,用于治疗粘多糖病VII。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免费获取StockNews.com关于Ultragenyx制药公司的研究报告(Rare)
- 细价股值得吗?你应该投资细价股吗?
- Zimmer Biomet盈利节节攀升,增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
- 内部人士和机构收购金刚狼全球
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Ultragenyx药学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Ultragenyx制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。